{"product_id":"alkermes-business-model-canvas","title":"Alkermes Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes Business Model Canvas: R\u0026amp;D, Partners \u0026amp; Revenue Insights for Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Alkermes’s strategic playbook with our concise Business Model Canvas—discover how its R\u0026amp;D-driven value propositions, partner ecosystem, and revenue mix translate into competitive advantage and growth potential; perfect for investors, consultants, and founders seeking actionable, ready-to-use insights. Download the full Word \u0026amp; Excel canvas for a section-by-section breakdown, financial implications, and benchmarking tools to accelerate your strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Biogen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes holds a license with Biogen for VUMERITY, generating royalties and manufacturing fees—Alkermes reported $39.6M in royalty and contract revenue from partnered products in 2024, largely driven by this asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes partners with global pharma firms to run its specialized Ireland manufacturing sites, producing complex formulations—including NanoCrystal (nanocrystal) enabled drugs—and in 2024 generated roughly $75–90M in third‑party manufacturing revenue, boosting plant utilization and diversifying income via multi‑year service agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes partners with top academic centers and CROs to run multi-site neuroscience trials; for example, late‑stage candidate ALKS 2680’s Phase 3 program leverages 30+ global sites and CRO services, cutting trial setup time by ~20% and widening access to diverse patient pools across North America and EMEA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Entities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlkermes partners with federal, state, and local public health agencies and criminal justice systems to distribute and administer VIVITROL for opioid and alcohol use disorder; as of 2024 VIVITROL had revenue contributions near $450M and was included in multiple state Medicaid formularies and 18 state-funded re-entry and correctional programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets opioid epidemic and alcohol dependence in public programs\u003c\/li\u003e\n\u003cli\u003eIntegration into Medicaid and 18 state correctional programs (2024)\u003c\/li\u003e\n\u003cli\u003eDrives ~450M in product revenue (2024) and improves access in funded recovery pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvocacy and Policy Stakeholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlkermes partners with mental health advocacy groups and policy organizations to shape CNS treatment access; in 2024 it supported initiatives tied to the Mental Health Parity Act and engaged with stakeholders influencing reimbursement for schizophrenia and bipolar therapies.\u003c\/p\u003e\n\u003cp\u003eThese ties inform product design and payer negotiations, helping secure formulary placement and reimbursement pathways that affect patient access to long-acting injectables and oral treatments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngaged with 12 national\/state advocacy groups in 2024\u003c\/li\u003e\n\u003cli\u003eAdvocacy efforts linked to coverage decisions impacting ~2.5M US patients with serious mental illness\u003c\/li\u003e\n\u003cli\u003ePolicy work focused on parity and access; influenced multiple state Medicaid formularies in 2023–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes 2024: Diversified revenue—VIVITROL $450M, manufacturing $75–90M, royalties $39.6M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes relies on Biogen licensing (VUMERITY royalties $39.6M in 2024), contract manufacturing in Ireland ($75–90M in 2024), CRO\/academic trial partnerships (ALKS‑2680 Phase 3, 30+ sites), public health\/criminal‑justice VIVITROL programs (~$450M revenue in 2024, 18 state programs), and advocacy\/payer engagement (12 groups, affecting ~2.5M patients in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense (Biogen)\u003c\/td\u003e\n\u003ctd\u003e$39.6M royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing (Ireland)\u003c\/td\u003e\n\u003ctd\u003e$75–90M revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/Academic Trials\u003c\/td\u003e\n\u003ctd\u003e30+ sites (ALKS‑2680)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Programs (VIVITROL)\u003c\/td\u003e\n\u003ctd\u003e$450M revenue; 18 states\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\/Payer\u003c\/td\u003e\n\u003ctd\u003e12 groups; ~2.5M patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Alkermes that maps customer segments, channels, value propositions, and revenue streams across the 9 BMC blocks with practical insights and competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Alkermes’ pharmaceutical strategy into a digestible one-page canvas, saving hours of structuring while enabling quick identification of core assets, partnerships, and revenue drivers for fast decision-making and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroscience Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes focuses on discovering and clinically developing CNS therapies, managing R\u0026amp;D from molecule design to Phase 3 trials; as of late 2025 its pipeline centers on orexin-2 receptor agonists and next-generation antipsychotics, with R\u0026amp;D spend of $360m in FY2024 and 5 programs in clinical stages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSophisticated Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes runs high-tech plants that produce hard-to-make formulations, notably long-acting injectables, with manufacturing revenue supporting its 2024 net product sales of $1.2 billion; the sites use proprietary delivery tech to achieve differentiated release profiles. The process follows FDA, EMA and ICH standards with tight quality control—batch release failure rates under 0.5% in 2024—creating a durable operational moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Targeted Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes runs targeted commercialization for LYBALVI and ARISTADA via a 200+ specialty sales force engaging psychiatrists and neurologists to boost prescribing; LYBALVI net product sales reached $268.5M and ARISTADA $143.4M in FY2024, driving marketing toward tolerability and adherence benefits backed by real‑world adherence gains ~15% vs comparators.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlkermes devotes substantial resources to FDA and EMA regulation, preparing NDAs\/MAAs and running post-market safety programs; in 2024 the company reported $1.2B R\u0026amp;D and regulatory spend across programs and partnerships, reflecting heavy compliance investment.\u003c\/p\u003e\n\u003cp\u003eRegulatory work ensures licenses to operate amid evolving laws and pharmacovigilance mandates, with routine submissions, label updates, and periodic safety reports tracked to avoid market restrictions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D\/regulatory spend: $1.2B (2024)\u003c\/li\u003e\n\u003cli\u003eNDA\/MAA preparation and submissions\u003c\/li\u003e\n\u003cli\u003eContinuous post-market safety monitoring\u003c\/li\u003e\n\u003cli\u003eOngoing compliance with FDA\/EMA rule changes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlkermes actively manages a broad patent portfolio for its drug-delivery platforms and molecular entities, filing new patents and defending ~150 issued U.S. and international patents (2025) to preserve exclusivity and support pricing that offsets \u0026gt;$1.2B cumulative R\u0026amp;D spend since 2010.\u003c\/p\u003e\n\u003cp\u003eEffective IP defense against generic challenges sustains peak-sales windows and underpins licensing and M\u0026amp;A value; legal and prosecution costs run into tens of millions annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~150 issued patents (U.S. \u0026amp; international, 2025)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;$1.2B cumulative R\u0026amp;D since 2010\u003c\/li\u003e\n\u003cli\u003eLegal\/prosecution costs: tens of millions\/year\u003c\/li\u003e\n\u003cli\u003eKey outcome: sustain market exclusivity and licensing value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes: $1.2B R\u0026amp;D \u0026amp; Sales, 200+ reps, \u0026lt;150 patents safeguarding CNS injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes runs discovery-to-Phase‑3 CNS R\u0026amp;D (R\u0026amp;D\/regulatory spend $1.2B in 2024), manufactures long‑acting injectables (net product sales $1.2B; batch failure \u0026lt;0.5% in 2024), commercializes LYBALVI ($268.5M) and ARISTADA ($143.4M) via a 200+ specialty sales force, and defends ~150 patents (2025) to protect exclusivity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/regulatory spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLYBALVI sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$268.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARISTADA sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$143.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch failure rate (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued patents (2025)\u003c\/td\u003e\n\u003ctd\u003e~150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Alkermes Business Model Canvas you’re previewing is the actual deliverable, not a mockup—this is a direct snapshot of the file you’ll receive after purchase. When you complete your order, you’ll get full access to the same professional, ready-to-edit document in the exact structure and formatting shown here. No placeholders or marketing samples—just the complete, usable canvas ready for presentation or customization. Buy with confidence: what you see is what you’ll download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749318046073,"sku":"alkermes-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alkermes-business-model-canvas.png?v=1772214132","url":"https:\/\/matrixbcg.com\/products\/alkermes-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}